Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Twist Bioscience Corporation (TWST)

NMS · Diagnostics & Research

$88.55+2.01 (+2.32%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$5.51B
P/E (TTM)
EPS
$-1.35
Div Yield
52W Range
$23.30–$105.47
Beta
2.12

Company overview

Next earnings: 2026-08-03(6d)

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Peers in Diagnostics & Research

All in industry →

Recent press releases

Twist Bioscience Corporation has not issued a press release in this window.

SEC filings

All filings →

Twist Bioscience Corporation has not filed an SEC document in this window.

Twist Bioscience Corporation has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
5,377,991 sh+31.7%
7,559,495 sh+12.4%
3,627,818 sh+17.4%
215,147 sh-78.9%
5,776,198 sh+0.1%
813,122 sh+171.2%
518,355 sh● NEW

People at Twist Bioscience Corporation

All people →

Quarterly financials

Full financials →
Revenue trend
12/24
$53.7M
NI -$31.6M
03/25
$55.2M
NI -$39.3M
06/25
$15.9M
NI $20.4M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $0.33
Prior: $-0.66
Revenue sparkline